Form 4: KALA BIO CFO Sells Shares Under 10b5-1 Plan

KALA BIO's Chief Financial Officer, Mary Reumuth, reported the sale of 33,197 common shares under a pre-arranged trading plan.

Summary

• Mary Reumuth, Chief Financial Officer of KALA BIO, Inc., reported transactions involving the company's common stock.
• On October 22, 2025, Reumuth sold 32,230 shares of common stock at a weighted average price of $0.83 per share, with prices ranging from $0.82 to $0.84.
• On October 23, 2025, an additional 967 shares of common stock were sold at a price of $0.82 per share.
• These sales were conducted pursuant to a Rule 10b5-1(c) trading plan, indicating they were pre-arranged.
• Following these transactions, Reumuth beneficially owns 28,906 shares, all of which are unvested Restricted Stock Units (RSUs).

Sentiment

Score: 3

Explanation: The sale of a significant number of shares by a key executive, even under a 10b5-1 plan, can be viewed negatively by investors as it reduces direct ownership and might signal a lack of confidence or a need for liquidity. The remaining holdings are entirely unvested RSUs.

Negatives

• Chief Financial Officer Mary Reumuth sold a significant portion of her directly owned common stock, totaling 33,197 shares.
• The sales occurred at prices between $0.82 and $0.84 per share.
• Her beneficial ownership of vested common stock is now zero, with remaining holdings consisting solely of 28,906 unvested RSUs.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal regarding the company's short-term prospects or valuation, despite the 10b5-1 plan.

Key Dates

Recommendation

The Chief Financial Officer's sale of a significant portion of her common stock, even under a pre-arranged 10b5-1 plan, typically signals a lack of immediate upside conviction or a personal liquidity event. While the 10b5-1 plan reduces the implication of opportunistic timing, the reduction in direct beneficial ownership to zero (excluding unvested RSUs) is a notable event. Investors should hold and monitor for further developments or fundamental changes, as this transaction alone does not provide a strong basis for a 'buy' or 'strong sell' recommendation without additional company-specific or industry-wide data.

Keywords

KALA BIO, KALA, Form 4, Insider Trading, Stock Sale, Mary Reumuth, Chief Financial Officer, CFO, SEC Filing, 10b5-1 plan